JP2023549187A5 - - Google Patents

Info

Publication number
JP2023549187A5
JP2023549187A5 JP2023528057A JP2023528057A JP2023549187A5 JP 2023549187 A5 JP2023549187 A5 JP 2023549187A5 JP 2023528057 A JP2023528057 A JP 2023528057A JP 2023528057 A JP2023528057 A JP 2023528057A JP 2023549187 A5 JP2023549187 A5 JP 2023549187A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
alkyl
tautomer
stereoisomer
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023528057A
Other languages
English (en)
Japanese (ja)
Other versions
JP7654075B2 (ja
JP2023549187A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062627 external-priority patent/WO2022103411A1/en
Publication of JP2023549187A publication Critical patent/JP2023549187A/ja
Publication of JP2023549187A5 publication Critical patent/JP2023549187A5/ja
Priority to JP2025009859A priority Critical patent/JP2025063287A/ja
Application granted granted Critical
Publication of JP7654075B2 publication Critical patent/JP7654075B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023528057A 2020-11-11 2020-11-30 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体 Active JP7654075B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009859A JP2025063287A (ja) 2020-11-11 2025-01-23 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112609P 2020-11-11 2020-11-11
US63/112,609 2020-11-11
PCT/US2020/062627 WO2022103411A1 (en) 2020-11-11 2020-11-30 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009859A Division JP2025063287A (ja) 2020-11-11 2025-01-23 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体

Publications (3)

Publication Number Publication Date
JP2023549187A JP2023549187A (ja) 2023-11-22
JP2023549187A5 true JP2023549187A5 (https=) 2023-12-07
JP7654075B2 JP7654075B2 (ja) 2025-03-31

Family

ID=73839136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023528057A Active JP7654075B2 (ja) 2020-11-11 2020-11-30 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体
JP2025009859A Pending JP2025063287A (ja) 2020-11-11 2025-01-23 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009859A Pending JP2025063287A (ja) 2020-11-11 2025-01-23 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体

Country Status (10)

Country Link
US (1) US20230391766A1 (https=)
EP (1) EP4244218A1 (https=)
JP (2) JP7654075B2 (https=)
KR (1) KR20230106637A (https=)
CN (1) CN116783183B (https=)
AU (1) AU2020476996A1 (https=)
CA (1) CA3197092A1 (https=)
IL (1) IL302678A (https=)
MX (1) MX2023005305A (https=)
WO (1) WO2022103411A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119677735A (zh) * 2022-05-11 2025-03-21 基因泰克公司 作为vhl配体的苯并噻唑化合物
WO2025162250A1 (zh) * 2024-02-04 2025-08-07 贝达药业股份有限公司 取代的三环化合物及其用途
WO2025228305A1 (zh) * 2024-04-28 2025-11-06 中国科学院上海药物研究所 一种蛋白降解剂缀合物及其偶联物
WO2026012475A1 (en) * 2024-07-12 2026-01-15 Ascentage Pharma (Suzhou) Co., Ltd. Vhl ligands and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
KR102668696B1 (ko) * 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
CN110573507B (zh) * 2017-04-14 2023-11-14 邓迪大学 小分子
US11547759B2 (en) * 2019-01-30 2023-01-10 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Similar Documents

Publication Publication Date Title
JP2023549187A5 (https=)
JP2020183410A5 (https=)
JP2011509309A5 (https=)
JP2020507589A5 (https=)
JP2013502431A5 (https=)
JP2022511477A5 (https=)
JP2022520061A5 (https=)
JP2021519263A5 (https=)
JP2014502641A5 (https=)
JP2016527217A5 (https=)
JP2016525102A5 (https=)
JP2022119852A5 (https=)
CA2614919C (en) 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
RU2017122824A (ru) Пирролопиримидиновое соединение
CN108892661A (zh) 治疗化合物和组合物
JP2019525900A5 (https=)
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
JP2020532550A5 (https=)
JP2023535815A5 (https=)
JP2011509301A5 (https=)
JP2019501879A5 (https=)
JP2018522861A5 (https=)
JP2024523822A5 (https=)
JP2020506878A5 (https=)
JP2020128426A5 (https=)